KK2845, a PBD dimer-containing antibody-drug conjugate targeting TIM-3-expressing AML

• Published in: Leukemia Vol. 39; no. 8; pp. 1848 - 1856
• Main Authors: Zou, Jian, Kinosada, Haruka, Takayanagi, Shin-ichiro, Ishii, Toshihiko, Amano, Toru, Nihira, Kaito, Kanie, Shohei, Adachi, Maiko, Tahara, Harunobu, Sakoda, Teppei, Kikushige, Yoshikane, Akashi, Koichi, Satou, Hidetaka
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 01.08.2025; Nature Publishing Group UK
• Subjects: Acute myeloid leukemia; Alanine; Animals; Antibodies; Antigens; Benzodiazepines - chemistry; Benzodiazepines - pharmacology; Biocompatibility; Bone marrow; Cell Line, Tumor; Chemotherapy; Cloning; Conjugates; Crosslinking; Cytotoxicity; Dimers; FDA approval; Female; Flow cytometry; Hematopoietic stem cells; Hepatitis A Virus Cellular Receptor 2 - antagonists & inhibitors; Hepatitis A Virus Cellular Receptor 2 - immunology; Hepatitis A Virus Cellular Receptor 2 - metabolism; Human subjects; Humans; Immunoconjugates - pharmacology; Immunoglobulin G; Intravenous infusion; Laboratories; Leukemia; Leukemia, Myeloid, Acute - drug therapy; Leukemia, Myeloid, Acute - metabolism; Leukemia, Myeloid, Acute - pathology; Lymphocytes T; Macaca fascicularis; Malignancy; Mice; Penicillin; Pharmacokinetics; Pharmacology; Pyrroles; R&D; Remission; Remission (Medicine); Research & development; Sialic Acid Binding Ig-like Lectin 3 - immunology; Stem cells; Toxicity; Valine; Xenograft Model Antitumor Assays; Japan

Acute myeloid leukemia (AML) is a common hematopoietic malignancy with high recurrence rates, and there is an urgent need for new therapeutic agents. T-cell immunoglobulin mucin-3 (TIM-3) is expressed on the surface of both LSCs and blasts in most AML patients, but not in normal hematopoietic stem c...